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Background and Purpose—Pilot trials suggest that glyceryl trinitrate (GTN; nitroglycerin) may improve outcome when 
administered early after stroke onset.
Methods—We undertook a multicentre, paramedic-delivered, ambulance-based, prospective randomized, sham-controlled, 
blinded-end point trial in adults with presumed stroke within 4 hours of ictus. Participants received transdermal GTN 
(5 mg) or a sham dressing (1:1) in the ambulance and then daily for three days in hospital. The primary outcome 
was the 7-level modified Rankin Scale at 90 days assessed by central telephone treatment-blinded follow-up. This 
prespecified subgroup analysis focuses on participants with an intracerebral hemorrhage as their index event. Analyses 
are intention-to-treat.
Results—Of 1149 participants with presumed stroke, 145 (13%; GTN, 74; sham, 71) had an intracerebral hemorrhage: 
time from onset to randomization median, 74 minutes (interquartile range, 45–110). By admission to hospital, blood 
pressure tended to be lower with GTN as compared with sham: mean, 4.4/3.5 mm Hg. The modified Rankin Scale score 
at 90 days was nonsignificantly higher in the GTN group: adjusted common odds ratio for poor outcome, 1.87 (95% 
CI, 0.98–3.57). A prespecified global analysis of 5 clinical outcomes (dependency, disability, cognition, quality of life, 
and mood) was worse with GTN; Mann-Whitney difference, 0.18 (95% CI, 0.01–0.35; Wei-Lachin test). GTN was 
associated with larger hematoma and growth, and more mass effect and midline shift on neuroimaging, and altered use 
of hospital resources. Death in hospital but not at day 90 was increased with GTN. There were no significant between-
group differences in serious adverse events.
Conclusions—Prehospital treatment with GTN worsened outcomes in patients with intracerebral hemorrhage. Since these 
results could relate to the play of chance, confounding, or a true effect of GTN, further randomized evidence on the use 
of vasodilators in ultra-acute intracerebral hemorrhage is needed.
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High blood pressure (BP) is common after the onset of acute intracerebral hemorrhage (ICH) and predicts a 
poor outcome, in part, by contributing to hematoma expan-
sion.1–5 However, trials of BP lowering in acute ICH have had 
conflicting results: INTERACT-2 (Second Intensive Blood 
Pressure Reduction in Acute Cerebral Haemorrhage Trial) was 
marginally positive,6 whereas INTERACT-1, the ICH subgroup 
of the ENOS trial (Efficacy of Nitric Oxide in Stroke), and 
the ATACH-2 (Second Antihypertensive Treatment of Acute 
Cerebral Haemorrhage) were neutral,7–9 and a subgroup anal-
ysis of the SCAST (Scandinavian Candesartan Acute Stroke) 
trial in ICH was negative.10 Consequently, the management of 
high BP in ICH remains unclear,11 and guidelines diverge in 
their recommendations over target levels of BP control.12–15
Glyceryl trinitrate (GTN)—a NO donor—lowered BP by 
systolic, 7.5/diastolic, 4.2 mm Hg in the ENOS ICH subgroup, 
as compared with control.8 In a meta-analysis and systematic 
review of individual patient data from 2 randomized trials, 
GTN was associated with improved functional outcome on the 
modified Rankin Scale (mRS) in 312 patients with ischemic 
stroke or ICH who were treated within 6 hours of the onset 
of symptoms.16 These findings led to conduct of the main 
phase RIGHT-2 (Rapid Intervention With Glyceryl Trinitrate 
in Hypertensive Stroke Trial), which assessed the effect of 
prehospital GTN in 1149 patients with ultra-early presumed 
acute stroke.17 However, in patients with a stroke or transient 
ischemic attack who were recruited within 4 hours (with me-
dian time from the onset of symptoms to randomization of 72 
minutes), GTN was associated with a nonsignificant worsen-
ing of mRS.17 Here, we present a detailed prespecified sub-
group analysis of the effect of GTN in RIGHT-2 patients with 
confirmed ICH.
Methods
Study Design and Study Population
RIGHT-2 was preregistered as ISRCTN26986053 on 5 March 2015. 
The trial opened to recruitment in September 2015, and the first 
participant was recruited on October 22, 2015. Individual partic-
ipant data will be shared with the Blood Pressure in Acute Stroke 
Collaboration and Virtual International Stroke Trials Archive; addi-
tional information is given in the online-only Data Supplement to this 
article. RIGHT-2 was a prospective multicenter paramedic-delivered 
ambulance-based sham-controlled participant- and outcome-blinded 
randomized controlled trial in adults with ultra-early presumed stroke 
in the United Kingdom.17,18 Briefly, adult patients were eligible for 
inclusion following an emergency 999 telephone call for presumed 
stroke if they presented within 4 hours of onset of their symptoms to 
a trial-trained paramedic from a participating ambulance service and 
could be taken to a participating hospital. Patients had to have a Face-
Arm-Speech-Time (FAST) score of 2 or 3 and a systolic BP ≥120 
mm Hg. Patients from a nursing home, or with reduced consciousness 
(Glasgow Coma Scale <8/15), hypoglycemia (capillary glucose <2.5 
mmol/L), or a witnessed seizure were excluded. Detailed inclusion 
and exclusion criteria are given in the online-only Data Supplement 
of the main trial publication.17 Additional information on the methods 
is given in the online-only Data Supplement to this article.
Treatment
Patients were randomly assigned, in 1:1 ratio, to receive transdermal 
GTN (nitroglycerin; 5 mg as Transiderm-Nitro 5; Novartis, Frimley 
UK) or sham (DuoDERM hydrocolloid dressing; Convatec, Flintshire 
United Kingdom). The first treatment (GTN or sham) was adminis-
tered by the paramedic immediately after randomization in the ambu-
lance, and further treatments were given for ≤3 days while in hospital.
Outcome Measures
The primary outcome was functional outcome assessed with the 
7-level mRS measured at 90 days post-randomization. Outcomes 
were recorded centrally by telephone by a trained assessor masked 
to treatment allocation, who used a structured questionnaire to ensure 
reliable scoring.19 This information was collected from a relative or 
carer if the participant was aphasic or for some other reason incapable 
of providing the information. If the participant/relative/carer could 
not be contacted by telephone, a questionnaire covering the same out-
come measures was sent by post.
Participants were seen at day 4 (or at hospital discharge, if ear-
lier) to determine adherence to treatment and assess neurological de-
terioration. Also recorded were the date of discharge from hospital, 
duration of stay, and discharge destination (to another hospital, insti-
tution, or home). Prespecified secondary clinical outcomes at day 90 
included activities of daily living (Barthel index), cognition (modi-
fied telephone Mini-Mental State Examination; Telephone Interview 
for Cognition Scale-modified), categorical verbal fluency using an-
imal naming, health-related quality of life (European Quality of Life 
5-dimensional 3 level, from which a health status utility value was 
calculated; European Quality of Life visual analogue scale), and 
mood (abbreviated Zung depression score), all as used in ENOS and 
described in the published protocol.18,20 Home time was calculated as 
the number of days between discharge and day 90.
Safety outcomes included all-cause and cause-specific death, 
investigator-reported hypotension or hypertension occurring dur-
ing the first 4 days, and serious adverse events (all up to day 5, and 
fatal thereafter to day 90). Serious adverse events were validated and 
categorized by expert adjudicators who were blinded to treatment 
assignment.
Neuroimaging Outcomes
Nonenhanced brain scans (computed tomography or magnetic res-
onance imaging) performed on arrival at hospital were collected for 
central adjudication by expert neuroradiologists masked to treatment 
assignment, symptoms, and follow-up imaging, using assessments 
updated from IST-3 (Third International Stroke Trial) and ENOS.20,21 
Computed tomography/magnetic resonance angiography was also 
performed in some centers according to local policy and adjudicated 
centrally. On the next day, a further computed tomography or mag-
netic resonance scan was performed to assess safety.
Statistical Analysis
Analyses followed the statistical analysis plan for the overall trial.22 
The primary outcome (shift on 7-level mRS) was assessed using 
ordinal logistic regression with adjustment for age, sex, premorbid 
mRS, baseline FAST score, systolic BP, and time from the onset of 
symptoms to randomization.22 The assumption of proportional odds 
was tested using the likelihood ratio test. We also performed un-
adjusted, per-protocol, and imputed (missing mRS data estimated 
using multiple regression-based imputation) sensitivity analyses for 
completeness. Heterogeneity of the treatment effect on the primary 
outcome was assessed for the purpose of hypothesis generation in 
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prespecified subgroups by adding an interaction term to an adjusted 
ordinal logistic regression model. Death was analyzed using adjusted 
Cox regression models. Other outcomes were assessed using adjusted 
binary logistic regression, Cox regression, ordinal logistic regres-
sion, multiple linear regression, and ANCOVA (BP). A prespecified 
global outcome (comprising ordered categorical or continuous data 
for mRS, Barthel index, Zung depression score, Telephone Interview 
for Cognition Scale-modified, and European Quality of Life 5-dimen-
sional health status utility value) was analyzed using the Wei-Lachin 
test.23 Participants who did not receive their assigned treatment or did 
not adhere to the protocol, or who had a stroke mimic, were all still 
followed up in full at day 90 and are included in the main analyses.
Results
Demographics
Of the 1149 recruited patients, 145 (13%; GTN, 74; sham, 
71) had a final hospital diagnosis of ICH based on clinical 
presentation and neuroimaging (Figure 1). Characteristics 
at baseline were well balanced between GTN and sham 
(Table 1): mean age, 73 (SD, 13) years; women, 64 (44%); 
FAST score, 3111 (77%); time from onset to randomization 
median, 74 (interquartile range, 45–110) minutes. Forty-one 
(44%) participants were taking an antithrombotic drug before 
their stroke. Adherence was excellent with 100% of partici-
pants receiving the first randomized treatment (Table I in the 
online-only Data Supplement).
Clinical Outcomes
After treatment, systolic and diastolic BP were nonsignifi-
cantly lower in the GTN group by mean 4.4/3.5 mm Hg at 
hospital admission, as compared with sham (Figure I in the 
online-only Data Supplement). One hundred forty-two (98%) 
of participants with ICH had the primary outcome (mRS) 
measured at 3 months (Table 2). We found some evidence, 
albeit statistically nonsignificant, that GTN was associ-
ated with a worse functional outcome, GTN median 5 (in-
terquartile range, 4–6) versus sham median 5 (interquartile 
Figure 1. CONSORT (Consolidated Standards 
of Reporting Trials) diagram in participants with 
a final diagnosis of intracerebral hemorrhage. 
GTN indicates glyceryl trinitrate.
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range, 3–6; adjusted common odds ratio [OR], 1.87; 95% CI, 
0.98–3.57; Figure 2). In 4 planned sensitivity analyses of the 
primary outcome,17 all comparisons were significant statisti-
cally with a worse mRS in the GTN as compared with sham 
group (Table 2). When assessing interactions of the effect of 
GTN on mRS by prespecified subgroups, a nonsignificant 
effect of time to randomization was apparent with participants 
recruited within 1 hour of symptom onset faring much worse 
with GTN (Figure 3).
After treatment in the ambulance, Glasgow Coma Scale 
and FAST scores had separated by hospital admission and were 
nonsignificantly worse in the GTN group as compared with 
sham (Figure IIA and IIB in the online-only Data Supplement). 
More than 40% of deaths occurred by day 4; GTN was as-
sociated with a significant increase in deaths in hospital and 
nonsignificant increase by day 90 (Table 2; Figure III in the 
online-only Data Supplement). GTN was associated with a 
worse discharge disposition (with more participants going to 
an institution) and quality of life and possibly more mood dis-
turbance. Global analyses based on all available data (n=79) 
and following imputation of missing data, and encompassing 
the original ordinal or continuous data for mRS, Barthel index, 
Telephone Interview for Cognition Scale-modified, Zung de-
pression score, and European Quality of Life 5-dimensional 
health status utility value, were significantly worse for GTN 
(Wei-Lachin test, Mann-Whitney difference, 0.18; 95% CI, 
0.01–0.35; Figure IV in the online-only Data Supplement).
In-Hospital Management and Treatment
While there may have been more use of antihypertensive 
therapy in the sham group as compared with the GTN group 
(Table II in the online-only Data Supplement), use of labet-
alol did not differ between the groups. Although admission to 
intensive care was uncommon (15%), ventilation was more 
common in participants randomized to GTN than sham (Table 
II in the online-only Data Supplement). Conversely, GTN was 
associated with less physiotherapy and speech therapy.
Neuroimaging Findings
Admission and day 2 to 4 scans were performed at median 2.3 
hours and median 28.9 hours after ICH, respectively (Table III 
in the online-only Data Supplement). On admission to hos-
pital, GTN was associated with larger hematoma on admission 
(assessed as maximum length: adjusted common OR, 1.95; 95% 
CI, 1.07–3.58; Table III in the online-only Data Supplement; 
Figure V in the online-only Data Supplement) and more mass 
effect (adjusted common OR, 2.42; 95% CI, 1.26–4.68; Figure 
VI in the online-only Data Supplement). There was no differ-
ence in intraventricular volume. On repeat imaging on day 2, 
GTN was associated with hematoma that were larger and more 
irregular in shape and increased perihematomal edema and 
midline shift (Table III in the online-only Data Supplement).
Discussion
This prespecified subgroup analysis of the RIGHT-2 trial 
explored the effect in those patients who were recruited with 
a final hospital diagnosis of ICH. Considering that the pri-
mary analysis for the overall trial population was neutral, 
ICH patients randomized to GTN had a worse outcome that 
was apparent across the primary end point and multiple other 
clinical dimensions covering dependency, quality of life, dis-
charge disposition and a global analysis of these, and meas-
ures of hematoma morphology; tendencies to more death and 
worse disability, cognition, and mood were also present. With 
matched characteristics at baseline, the negative effect of GTN 
Table 1. Baseline Characteristics
All GTN Sham
No. of patients 145 74 71
Ambulance data
Age, y 73.1 (13) 73.5 (12) 72.7 (14)
Sex, female (%) 64 (44) 35 (47) 29 (41)
Time, min
  Onset to randomization, h 74 [45–110] 70 [45–121] 75 [45–101]
  <1 (%) 52 (36) 27 (36) 25 (35)
  1–2 (%) 62 (43) 28 (38) 34 (48)
  >2 (%) 31 (21) 19 (26) 12 (17)
ECG, AF/flutter (%) 16 (14) 10 (17) 6 (10)
Systolic BP, mm Hg 176 (27) 176 (26) 176 (28)
Diastolic BP, mm Hg 100 (22) 99 (23) 101 (21)
Heart rate, bpm 82 (17) 82 (17) 81 (16)
Glasgow Coma Scale, (/15) 13.6 (1.8) 13.7 (1.6) 13.6 (2.0)
  <14 (%) 49 (34) 27 (37) 22 (31)
FAST score (/3) 2.8 (0.4) 2.8 (0.4) 2.7 (0.5)
  3 (%) 111 (77) 57 (77) 54 (76)
Hospital admission
Time, min
  Randomization to hospital 25 [17–34] 21.5 [16–33] 26 [19–37]
  Randomization to imaging 55 [41–71] 53.5 [41–74] 56 [42–69]
Ethnic group, nonwhite (%) 16 (11) 7 (10) 9 (13)
Premorbid mRS >2 (%) 17 (12) 12 (16) 5 (7)
Medical history (%)
  Hypertension 82 (57) 41 (55) 41 (59)
  Diabetes mellitus 22 (15) 12 (16) 10 (14)
  Previous stroke 27 (19) 12 (16) 15 (21)
  Ischemic heart disease 16 (11) 7 (10) 9 (13)
  Smoking, current 10 (10) 3 (6) 7 (14)
  Alcohol use, >12 upw 7 (7) 3 (6) 4 (9)
Antithrombotic therapy 41 (44) 17 (35) 24 (53)
Antiplatelet therapy* 25 (27) 8 (17) 17 (38)
Oral anticoagulation 16 (17) 9 (19) 7 (16)
Data are number (%), median [interquartile range], or mean (SD). 
Antithrombotic therapy=oral anticoagulation or antiplatelet therapy. AF 
indicates atrial fibrillation; BP, blood pressure; FAST, Face-Arm-Speech-Time; 
GTN, glyceryl trinitrate; mRS, modified Rankin Scale; and upw, units per week.
*Prior antiplatelet therapy was more commonly taken by participants 
randomized to sham.
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Table 2. Primary Outcome and Key Secondary Outcomes
n GTN Sham aOR/acOR/DIM (95% CI)
Day 90 mRS, maximum score of 6 (primary outcome) 142 5 [4 to 6] 5 [3 to 6] 1.87 (0.98 to 3.57)
Sensitivity analyses     
Unadjusted 142 5 [4 to 6] 5 [3 to 6] 2.06 (1.13 to 3.78)
Mean 142 4.9 (1.4) 4.3 (1.6) 0.44 (0.02 to 0.87)
Per protocol 121 6 [4.5 to 6] 5 [3 to 6] 2.21 (1.07 to 4.53)
Imputed 145 5 [4 to 6] 5 [3 to 6] 1.92 (1.01 to 3.64)
Hospital admission     
NIHSS, maximum score of 42 117 16.5 (7.0) 14.3 (7.4) 1.55 (−0.78 to 3.88)
GCS, maximum score of 15 144 11.9 (3.6) 12.8 (3.0) −0.90 (−1.93 to 0.12)
FAST, maximum score of 3 129 2.8 (0.5) 2.6 (0.8) 0.16 (−0.04 to 0.36)
OCSP, TACS (%) 141 41 (57.7) 37 (52.9) 1.33 (0.63 to 2.80)
Outcomes on day 4 (or discharge)     
Death (%) 145 15 (20.3) 12 (16.9) 1.61 (0.63 to 4.14)
Neurological deterioration (%) 85 20 (46.5) 14 (33.3) 1.65 (0.61 to 4.49)
Headache, clinical (%) 142 11 (15.1) 8 (11.6) 1.41 (0.51 to 3.92)
Hypotension, clinical (%) 142 5 (6.8) 0 (0.0) …
Hypertension, clinical (%) 142 34 (46.6) 31 (44.9) 0.97 (0.45 to 2.07)
Feeding, nonoral (%) 133 44 (65.7) 42 (63.6) 0.95 (0.43 to 2.11)
Patients with an SAE 145 39 (53.0) 33 (46.0) 1.28 (0.64 to 2.56)
Hospital events     
Length of stay, d 145 27.4 (43.6) 31.5 (42.5) −7.52 (−20.60 to 5.55)
Died (%) 145 34 (45.9) 21 (29.6) 2.26 (1.03 to 4.95)
Died or in an institution (%) 142 55 (76.4) 47 (67.1) 1.44 (0.63 to 3.30)
Outcomes on day 90     
Death (%) 144 35 (47.9) 23 (32.4) 1.50 (0.86 to 2.62)
Disposition, maximum score of 3* 140 2 [2 to 3] 2 [1 to 3] 2.31 (1.17 to 4.57)
EQ-5D-HSUV, maximum score of 1† 137 0.1 (0.2) 0.2 (0.4) −0.13 (−0.23 to −0.03)
EQ-VAS (/100)† 130 24.4 (30.5) 34.6 (33.5) −8.64 (−18.10 to 0.88)
BI, maximum score of 100† 139 24.4 (39.7) 36.1 (42.8) −8.53 (−20.40 to 3.34)
TICS-M, maximum score of 39†‡ 79 3.6 (9.3) 6.5 (11.4) −2.38 (−6.06 to 1.30)
tMMSE, maximum score of 21†‡ 79 3.3 (8.2) 5.6 (9.8) −2.02 (−5.21 to 1.17)
Animal naming†‡ 79 1.9 (6.2) 5 (9.4) −2.90 (−5.83 to 0.02)
ZDS, maximum score of 102.5†‡ 87 89.6 (24.2) 78.9 (29.7) 8.46 (−0.80 to 17.73)
Global analysis, Wei-Lachin‡ 79 … … 0.18 (0.01 to 0.35)
Global analysis, Wei-Lachin (with imputation) 145 … … 0.16 (0.02 to 0.30)
Global analysis, Wald‡ 79 … … 2.17 (1.10 to 4.28)
Global analysis, Wald (with imputation) 145 … … 1.92 (1.05 to 3.51)
Home time, d 113 12.7 (29.8) 19.6 (33.9) −4.35 (−14.40 to 5.66)
Data are number (%), median [interquartile quartile range], or mean (SD). Comparison by BLR, Cox proportional hazards regression, OLR, or MLR, with adjustment 
for age, sex, premorbid mRS, FAST, pretreatment SBP, and time to randomization (unless stated). The effect of treatment for GTN vs sham is shown as acOR, aOR, 
aHR, or aDIM, with 95% CIs. Hypertension: SBP >180 mm Hg; hypotension: SBP <90 mmHg. acOR indicates adjusted common odds ratio; aDIM, adjusted difference in 
means; aHR, adjusted hazard ratio; aOR, adjusted odds ratio; BI, Barthel index; BLR, binary logistic regression; DIM, difference in means; EQ-5D, European Quality of 
Life, 5 dimensional; EQ-VAS, European Quality of Life visual analogue scale; FAST, Face-Arm-Speech-Time; GCS, Glasgow Coma Scale; GTN, glyceryl trinitrate; HSUV, 
health status utility value; MLR, multiple linear regression; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OCSP, Oxford Community 
Stroke Project; OLR, ordinal logistic regression; SAE, serious adverse event; SBP, systolic blood pressure; TACS, total anterior circulation syndrome; TICS-M, Telephone 
Interview for Cognition Scale-modified; tMMSE, telephone modified Mini-Mental State Examination; and ZDS, Zung Depression Scale.
*Disposition: home (score of 1), institution or in hospital (score of 2), died (score of 3) by day 90.
†Death assigned: BI, 5; animal naming, 1; EQ-VAS, 1; home time, 1; tMMSE, 1; TICS-M, 1; EQ-5D HSUV, 0; GCS, 2; NIHSS, 43; ZDS. 102.5.
‡Some participants with poor outcomes or dysphasia could not answer cognition and mood questions.
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appeared to start rapidly after patch placement manifesting as 
a tendency to early separation of Glasgow Coma Scale and 
FAST scores by 25 minutes; findings of larger hematoma and 
more mass effect on imaging shortly after hospital admission 
by 55 minutes; altered hospital activity with patients random-
ized to GTN needing more ventilation, less physiotherapy 
Figure 2. Shift in modified Rankin Scale in 
145 participants with a final diagnosis of 
intracerebral hemorrhage by treatment group. 
Comparison by ordinal logistic regression with 
adjustment for age, sex, premorbid modified 
Rankin Scale, face-arm-speech time test, pre-
treatment systolic blood pressure, and time 
to randomization. The effect of treatment for 
glyceryl trinitrate (GTN) vs sham is shown as 
adjusted common odds ratio (acOR).
Figure 3. Forest plot showing modified Rankin 
Scale (mRS) in prespecified subgroups of par-
ticipants with intracerebral hemorrhage, with 
P value for interaction. Heterogeneity of the 
treatment effect on the primary outcome was 
assessed by adding an interaction term to an 
ordinal logistic regression model with adjust-
ment as in Figure 2. BP indicates blood pres-
sure; FAST, Face-Arm-Speech-Time; and GTN, 
glyceryl trinitrate.
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and speech therapy, and increased death in hospital; and then 
worse outcome at 90 days.
The finding that GTN appears to worsen outcome in ICH 
when administered in the ultra-acute period after stroke was 
unexpected since a meta-analysis of data from 2 trials sug-
gested that GTN improved outcome when administered to 
patients with ICH within 6 hours of onset.16 A key difference 
between these trials is that the median time from ICH onset to 
randomization was 74 minutes in RIGHT-2 versus 280 minutes 
in ENOS early ICH.24 In the overall stroke/transient ischemic 
attack population in RIGHT-2, there was a profound time-by-
treatment interaction with a negative effect of GTN on mRS in 
patients randomized within 1 hour and a tendency to benefit 
in those randomized beyond 2 hours. Although this time-by-
treatment interaction was not significant in the ICH subgroup 
alone, GTN worsened outcome when randomized within 1 
hour (OR, 8.39; 95% CI, 2.22–31.69) and yet was associated 
with a positive tendency beyond 2 hours (Figure 3). Further, 
RIGHT-2 participants had more premorbid dependency, an 
increased prevalence of baseline background imaging changes, 
and hematoma that were more than twice the size observed 
in ENOS (Table III in the online-only Data Supplement). 
Finally, treatment was given for 7 days in ENOS and only 4 
days in RIGHT-2. These differences may explain the varia-
tion in overall outcome and response to GTN seen between 
RIGHT/ENOS early and RIGHT-2. Potential mechanisms for 
why GTN worsens outcome if given early after ICH include 
inhibiting the first (vasoconstriction) and second (platelet plug-
ging) phases of hemostasis, as detailed in the online-only Data 
Supplement. This time-dependent pattern of negative-neutral-
positive-neutral findings is novel and contrasts with reperfusion 
therapies that exhibit a positive-neutral time course. Hence, it 
could be hypothesized that nonreperfusion therapies should 
not be started in the ultra-acute period, perhaps reflecting that 
the early stunned and fragile brain does not respond well to 
active modulation by external interventions.
The subgroup analysis presented here has several strengths. 
First, it was prespecified and follows on from previous work 
suggesting that GTN would improve outcome in the hyper-
acute phase of stroke, including in ICH.16 Second, RIGHT-2 
had limited exclusion criteria; so the results probably apply to 
most patients with prehospital ICH. Third, participants were 
masked to treatment and unaware of treatment assignment at 
day 90. Last, the results show clear internal validity with par-
allel negative effects of GTN seen on clinical, radiological, 
and hospital activity measures.
Similarly, there are several limitations. First, the ICH 
sample in RIGHT-2 was small (n=145) although this was 
driven by the overall sample size of the trial (n=1149) and the 
proportion of these with ICH (n=13%). In reality, the propor-
tion of ICH of overall stroke was high at 24% and larger than 
seen in hospital-based trials reflecting the relatively unselected 
nature of the study. Second, technically, this substudy is neu-
tral since the CIs for the result of the analysis of the primary 
outcome analysis (ordinal shift in mRS) narrowly crossed OR 
of 1.00. The small sample size and technical neutral result 
raise the possibility that the results reflect the play of chance 
or systematic confounding. Chance is unlikely in the presence 
of internally consistent results across clinical, imaging, and 
hospital activity findings. Systematic confounding, due per-
haps to imbalances in unmeasured demographic, clinical, or 
imaging variables at baseline, is possible and highlights the 
challenges of adequately describing participants in the time-
limited prehospital ambulance environment.
In summary, we have shown that the ultra-acute use of 
GTN may be harmful in patients with ICH and especially 
within 2 hours. This could result from inhibition of the earliest 
vasoconstrictory and platelet plugging phases of hemostasis, 
mechanisms that might apply to other vasodilators. In this re-
spect, RIGHT-2 is the first large trial to test the effect of inhib-
iting vasoconstriction in this time-critical period after ICH. 
However, further trials are needed to determine whether the 
results reflect systematic confounding or a real effect of this 
agent or BP-lowering treatment more broadly, particularly as 
vasodilators/antihypertensive agents are widely used in neuro-
critical care in ICH patients. In the meantime, we recommend 
that GTN (and probably other nitrovasodilators) should not be 
used in the prehospital setting in patients with possible stroke 
outside of a randomized controlled trial.
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